9 June 2017:link here
Read more about Adherium Appoints New CEO to Drive Global Growth
US-based CEO aligns with Avita’s increasing US orientation with BARDA contract, completed Phase 3 trial, imminent PMA submission, and pending US approval & commercialization • Mike Perry former Novartis Executive...
Read more about Dr Michael S. Perry appointed Avita Medical CEO
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces the appointment of Paul C. Grint, M.D.
Directors take up to 100 per cent of fees in shares • Follows shareholder approval of employee share plan in November last year Northridge, CA, USA, Perth, Australia and Cambridge,...
By Amina Zafar, CBC News Posted: Apr 28, 2017 8:14 PM ET Last Updated: Apr 29, 2017 7:32 AM ET - Link here
Read more about Avita Medical Announces Positive Results from Pivotal Trial
15/05/2017 - link here
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces financial results for the quarter ended March 31,...
Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 11 May 2017 — link here
Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 10 May 2017 — link here